Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIIa in Brain Contusions
NCT00123591Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2005
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of coagulation factor VIIa in cerebral contusion (6 arms), sponsored by Novo Nordisk. Primary endpoint: Safety of Recombinant Activated Factor VII at 15 days. Started Jan 2005; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
cerebral contusion
Beyond the preview
Go deeper on NCT00123591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123591.